Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 Single-Arm Ravulizumab Study in High-Dose Eculizumab-Treated PNH Adults
2019-003440-74Phase 4Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Free C5-associated breakthrough hemolysis through Day 351. Status: unknown.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2019-003440-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003440-74.